CL2017003143A1 - Composición multi-péptido. - Google Patents
Composición multi-péptido.Info
- Publication number
- CL2017003143A1 CL2017003143A1 CL2017003143A CL2017003143A CL2017003143A1 CL 2017003143 A1 CL2017003143 A1 CL 2017003143A1 CL 2017003143 A CL2017003143 A CL 2017003143A CL 2017003143 A CL2017003143 A CL 2017003143A CL 2017003143 A1 CL2017003143 A1 CL 2017003143A1
- Authority
- CL
- Chile
- Prior art keywords
- combination
- peptides
- peptide composition
- refers
- specific peptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
<p>LA INVENCIÓN SE REFIERE A UNA COMBINACIÓN DE PÉPTIDOS ESPECÍFICA. LA COMBINACIÓN DE PÉPTIDOS PUEDE ESTAR PRESENTE EN UNA COMPOSICIÓN FARMACÉUTICAMENTE ACEPTABLE. LA COMBINACIÓN DE PÉPTIDOS PUEDE USARSE EN LA TERAPIA O PREVENCIÓN DE LA DIABETES TIPO 1 (DT1). LA INVENCIÓN TAMBIÉN SE REFIERE A UN MÉTODO PARA DIAGNOSTICAR O DETERMINAR LA EFICACIA DEL TRATAMIENTO, EL MÉTODO UTILIZA LA COMBINACIÓN DE PÉPTIDOS ESPECÍFICA.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1510056.3A GB201510056D0 (en) | 2015-06-10 | 2015-06-10 | Multi-peptide composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017003143A1 true CL2017003143A1 (es) | 2018-05-18 |
Family
ID=53785229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017003143A CL2017003143A1 (es) | 2015-06-10 | 2017-12-07 | Composición multi-péptido. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US11400131B2 (es) |
| EP (1) | EP3307298B1 (es) |
| JP (1) | JP6969790B2 (es) |
| KR (1) | KR20180023948A (es) |
| CN (1) | CN107896494B (es) |
| AR (1) | AR104947A1 (es) |
| AU (1) | AU2016275295B2 (es) |
| BR (1) | BR112017026537A2 (es) |
| CL (1) | CL2017003143A1 (es) |
| CO (1) | CO2017012986A2 (es) |
| EA (1) | EA201890007A1 (es) |
| EC (1) | ECSP18001655A (es) |
| ES (1) | ES2778630T3 (es) |
| GB (1) | GB201510056D0 (es) |
| HK (1) | HK1253094A1 (es) |
| IL (1) | IL256199B2 (es) |
| MA (1) | MA41668A1 (es) |
| MX (1) | MX2017015658A (es) |
| PE (1) | PE20180450A1 (es) |
| PH (1) | PH12017501918A1 (es) |
| PL (1) | PL3307298T3 (es) |
| TN (1) | TN2017000517A1 (es) |
| TW (1) | TW201712027A (es) |
| UY (1) | UY36722A (es) |
| WO (1) | WO2016198887A1 (es) |
| ZA (1) | ZA201707873B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201913408D0 (en) * | 2019-09-17 | 2019-10-30 | King S College London | Proinsulin peptides for type 1 diabetes |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002542488A (ja) * | 1999-04-21 | 2002-12-10 | ザイコス インク． | 疾患を促進するｃｄ４＋ｔリンパ球によって認識されるペプチドエピトープ |
| US20030045467A1 (en) * | 2001-01-05 | 2003-03-06 | Tihamer Orban | Autoantigen composition |
| GB0402129D0 (en) * | 2004-01-30 | 2004-03-03 | King S College London | Therapeutic and diagnostic peptides |
| EP1709070B1 (en) * | 2004-01-30 | 2013-05-29 | King's College London | Peptides for treatment of autoimmune diseases |
| AU2005213449A1 (en) * | 2004-02-04 | 2005-08-25 | The La Jolla Institute For Allergy And Immunology | Anti-CD3 and antigen-specific immunotherapy to treat autoimmunity |
| WO2008083331A2 (en) * | 2006-12-29 | 2008-07-10 | The Regents Of The University Of Colorado | Diagnostic and therapeutic target for autoimmune diseases and uses thereof |
| JP2014507160A (ja) * | 2011-02-22 | 2014-03-27 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． | 循環バイオマーカー |
| CN104203263A (zh) * | 2012-03-01 | 2014-12-10 | 耶达研究与发展有限公司 | 利用HSP60衍生肽再生胰岛β细胞 |
-
2015
- 2015-06-10 GB GBGB1510056.3A patent/GB201510056D0/en not_active Ceased
-
2016
- 2016-06-08 TW TW105118185A patent/TW201712027A/zh unknown
- 2016-06-09 AR ARP160101718A patent/AR104947A1/es unknown
- 2016-06-10 ES ES16729347T patent/ES2778630T3/es active Active
- 2016-06-10 TN TNP/2017/000517A patent/TN2017000517A1/en unknown
- 2016-06-10 US US15/580,791 patent/US11400131B2/en active Active
- 2016-06-10 PE PE2017002531A patent/PE20180450A1/es unknown
- 2016-06-10 JP JP2017564393A patent/JP6969790B2/ja active Active
- 2016-06-10 BR BR112017026537-0A patent/BR112017026537A2/pt not_active Application Discontinuation
- 2016-06-10 UY UY0001036722A patent/UY36722A/es not_active Application Discontinuation
- 2016-06-10 PL PL16729347T patent/PL3307298T3/pl unknown
- 2016-06-10 WO PCT/GB2016/051726 patent/WO2016198887A1/en not_active Ceased
- 2016-06-10 KR KR1020187000588A patent/KR20180023948A/ko not_active Withdrawn
- 2016-06-10 CN CN201680033887.1A patent/CN107896494B/zh active Active
- 2016-06-10 EP EP16729347.1A patent/EP3307298B1/en active Active
- 2016-06-10 MX MX2017015658A patent/MX2017015658A/es unknown
- 2016-06-10 IL IL256199A patent/IL256199B2/en unknown
- 2016-06-10 AU AU2016275295A patent/AU2016275295B2/en active Active
- 2016-06-10 EA EA201890007A patent/EA201890007A1/ru unknown
- 2016-06-10 MA MA41668A patent/MA41668A1/fr unknown
- 2016-06-10 HK HK18112481.1A patent/HK1253094A1/zh unknown
-
2017
- 2017-10-20 PH PH12017501918A patent/PH12017501918A1/en unknown
- 2017-11-20 ZA ZA2017/07873A patent/ZA201707873B/en unknown
- 2017-12-07 CL CL2017003143A patent/CL2017003143A1/es unknown
- 2017-12-18 CO CONC2017/0012986A patent/CO2017012986A2/es unknown
-
2018
- 2018-01-10 EC ECIEPI20181655A patent/ECSP18001655A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016198887A1 (en) | 2016-12-15 |
| HK1253094A1 (zh) | 2019-06-06 |
| AU2016275295B2 (en) | 2021-12-09 |
| EA201890007A1 (ru) | 2018-05-31 |
| EP3307298A1 (en) | 2018-04-18 |
| CA2984957A1 (en) | 2016-12-15 |
| AU2016275295A1 (en) | 2017-12-07 |
| JP6969790B2 (ja) | 2021-11-24 |
| CN107896494B (zh) | 2021-09-03 |
| ECSP18001655A (es) | 2018-10-31 |
| IL256199B2 (en) | 2024-11-01 |
| US11400131B2 (en) | 2022-08-02 |
| TN2017000517A1 (en) | 2019-04-12 |
| US20180221434A1 (en) | 2018-08-09 |
| CN107896494A (zh) | 2018-04-10 |
| JP2018524301A (ja) | 2018-08-30 |
| GB201510056D0 (en) | 2015-07-22 |
| PE20180450A1 (es) | 2018-03-05 |
| ES2778630T3 (es) | 2020-08-11 |
| PH12017501918A1 (en) | 2018-03-19 |
| IL256199A (en) | 2018-02-28 |
| UY36722A (es) | 2017-01-31 |
| AR104947A1 (es) | 2017-08-23 |
| IL256199B1 (en) | 2024-07-01 |
| KR20180023948A (ko) | 2018-03-07 |
| TW201712027A (zh) | 2017-04-01 |
| MX2017015658A (es) | 2018-08-15 |
| BR112017026537A2 (pt) | 2019-11-12 |
| CO2017012986A2 (es) | 2018-03-09 |
| PL3307298T3 (pl) | 2020-06-29 |
| EP3307298B1 (en) | 2020-01-15 |
| ZA201707873B (en) | 2019-05-29 |
| MA41668A1 (fr) | 2018-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123033T1 (el) | Σπειροκυκλικοι αναστολεις της καθεψινης c | |
| CO2020003478A2 (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| ECSP17029203A (es) | Inhibidor de cinasa aurora a | |
| CL2015001279A1 (es) | Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras. | |
| WO2015095811A8 (en) | Combination therapy with neoantigen vaccine | |
| AR094970A1 (es) | Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer | |
| MX2015013948A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| CL2017001483A1 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| MX2016016534A (es) | Compuestos ppar para uso en el tratamiento de enfermedades fibroticas. | |
| CL2017001843A1 (es) | Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2. | |
| MX2016011938A (es) | Composicion farmaceutica liquida. | |
| CL2017001904A1 (es) | Composición para el tratamiento de enfermedad veno-oclusiva hepática. | |
| MX2017015926A (es) | Uso de derivados de bencimidazol para escape acido nocturno. | |
| MX2019001577A (es) | Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal. | |
| WO2015112902A3 (en) | CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN | |
| MX2016011115A (es) | Terapia inmunorreguladora contra autoinmunidad en diabetes tipo 1. | |
| DOP2019000194A (es) | Derivados de pirrolotriazina como inhibidor de cinasas | |
| CR20160353A (es) | Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| EA201790552A1 (ru) | Применение элсиглутида для лечения мукозита желудочно-кишечного тракта, включая индуцированную химиотерапией диарею | |
| MX2016008968A (es) | Compuestos organicos. | |
| AR093327A1 (es) | Analogos quimericos de somatostatina-dopamina | |
| MD4763B1 (ro) | Compoziţie farmaceutică | |
| ES2721003T3 (es) | Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis | |
| ECSP18001655A (es) | Composición de péptidos múltiples |